# A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

Source: https://onco.cc/trials/nct07011056/  
OnCo record `nct07011056` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Purinostat in diffuse large B-cell lymphoma, now recruiting.

## Summary

A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma is a phase 3 interventional study registered as NCT07011056, led by Chengdu Zenitar Biomedical Technology, and recruiting on the registry. Official title: A Randomised, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of the Purinostat Mesylate for Injection (PM) Compared to Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). Planned enrolment is 390 participants (estimated). The study started in 2025-07-18 and primary completion is expected in 2029-06-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07011056
- Phase: 3
- Setting: A Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of the Purinostat Mesylate for Injection (PM) Compared to Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
- Sponsor: Chengdu Zenitar Biomedical Technology
- Enrolled: 390

## Sources

- ClinicalTrials.gov NCT07011056: https://clinicaltrials.gov/study/NCT07011056

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Purinostat](https://onco.cc/drugs/purinostat/)
- companies: [Chengdu Zenitar Biomedical Technology](https://onco.cc/companies/chengdu-zenitar-biomedical-technology/)

---
JSON: https://onco.cc/api/v1/entities/nct07011056.json